Dyslipidemias
Dyslipidemias(血脂异常)
Dyslipidemias 相关产品(102)
- GC47397Gemfibrozil-d6CAS: 1184986-45-5纯度: >99.00%
An internal standard for the quantification of gemfibrozil
- GC47404Glipizide-d11CAS: 1189426-07-0纯度: >98.00%
An internal standard for the quantification of glipizide
- GC47436HT-2 Toxin-13C22CAS: 1486469-92-4纯度: >98.00%
An internal standard for the quantification of HT-2 toxin
- GC47824Olmesartan Medoxomil-d6CAS: 1127298-67-2纯度: >99.00%
An internal standard for the quantification of olmesartan medoxomil
- GC47858Palmitelaidic Acid-d13CAS: 2692623-91-7纯度: >99.00%
A neuropeptide with diverse biological activities
- GC47864Palmitoleic Acid-d14CAS: 184708-66-5纯度: >99.00%
An internal standard for the quantification of palmitoleic acid
- GC48054Rimonabant-d10CAS: 929221-88-5纯度: >99.00%
An internal standard for the quantification of rimonabant
- GC48283α-Linolenic Acid-d14CAS: 1622944-40-4纯度: >99.00%
An internal standard for the quantification of α-Linolenic acid
- GC49236Orlistat-d3CAS: 1356930-46-5纯度: >99.00%
An internal standard for the quantification of orlistat
- GC49389Tritylolmesartan MedoxomilCAS: 144690-92-6纯度: >98.00%
An intermediate in the synthesis of olmesartan medoxomil
- GC49393all-trans-13,14-DihydroretinolCAS: 115797-14-3纯度: >95.00%
A metabolite of all-trans retinoic acid
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC47367 | Fluvastatin (sodium salt hydrate) | - | >98.00% | |
An HMG-CoA reductase inhibitor | ||||
| GC47397 | Gemfibrozil-d6 | 1184986-45-5 | >99.00% | |
An internal standard for the quantification of gemfibrozil | ||||
| GC47404 | Glipizide-d11 | 1189426-07-0 | >98.00% | |
An internal standard for the quantification of glipizide | ||||
| GC47436 | HT-2 Toxin-13C22 | 1486469-92-4 | >98.00% | |
An internal standard for the quantification of HT-2 toxin | ||||
| GC47815 | Octacosanoic Acid | 506-48-9 | >95.00% | |
A very long-chain saturated fatty acid | ||||
| GC47824 | Olmesartan Medoxomil-d6 | 1127298-67-2 | >99.00% | |
An internal standard for the quantification of olmesartan medoxomil | ||||
| GC47858 | Palmitelaidic Acid-d13 | 2692623-91-7 | >99.00% | |
A neuropeptide with diverse biological activities | ||||
| GC47864 | Palmitoleic Acid-d14 | 184708-66-5 | >99.00% | |
An internal standard for the quantification of palmitoleic acid | ||||
| GC48054 | Rimonabant-d10 | 929221-88-5 | >99.00% | |
An internal standard for the quantification of rimonabant | ||||
| GC48120 | T-2 Toxin-13C24 | 21259-20-1 | >98.00% | |
A neuropeptide with diverse biological activities | ||||
| GC48196 | trans-Vaccenic Acid-d13 | - | >99.00% | |
A neuropeptide with diverse biological activities | ||||
| GC48272 | ZLY032 | 2314465-67-1 | >98.00% | |
A dual FFAR1 and PPARδ agonist | ||||
| GC48283 | α-Linolenic Acid-d14 | 1622944-40-4 | >99.00% | |
An internal standard for the quantification of α-Linolenic acid | ||||
| GC48418 | N-(2-Poc-ethyl)betulin amide | - | >95.00% | |
An alkyne derivative of betulin | ||||
| GC48449 | 28-(Poc-amino)betulin | - | >95.00% | |
An alkyne derivative of betulin | ||||
| GC48521 | KRP 297 | 213252-19-8 | >98.00% | |
A dual agonist of PPARα and PPARγ | ||||
| GC48719 | (S)-Canadine | 5096-57-1 | >98.00% | |
An alkaloid with insecticidal activity | ||||
| GC48778 | Gadoleic Acid | 29204-02-2 | >98.00% | |
A monounsaturated fatty acid | ||||
| GC49141 | Triacontanoic Acid | 506-50-3 | >99.00% | |
A very long-chain saturated fatty acid | ||||
| GC49236 | Orlistat-d3 | 1356930-46-5 | >99.00% | |
An internal standard for the quantification of orlistat | ||||
| GC49333 | SH-42 | 2143952-36-5 | >95.00% | |
An inhibitor of DHCR24 | ||||
| GC49387 | Berberine-d6 (chloride) | - | >99.00% | |
An internal standard for the quantification of berberine | ||||
| GC49389 | Tritylolmesartan Medoxomil | 144690-92-6 | >98.00% | |
An intermediate in the synthesis of olmesartan medoxomil | ||||
| GC49393 | all-trans-13,14-Dihydroretinol | 115797-14-3 | >95.00% | |
A metabolite of all-trans retinoic acid | ||||